IP Library Granted Patent US 11,945,859
Granted Patent B2
US 11,945,859 · App. 16/715,580 · Granted Apr 2, 2024

Protein solution formulation containing high concentration of an anti-VEGF antibody

Inventors: Juergen Sigg (Loerrach, DE); Pamela De Moor (Palo Alto, CA)
Assignee: NOVARTIS AG
C07K16/22A61K9/0048A61K47/26
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,945,859
App. No.
16/715,580
Granted
Apr 2, 2024
Kind
B2
Abstract

The present invention provides anti-VEGF antibodies formulated as high concentration, aqueous pharmaceutical compositions, suitable for an injection, preferably an intravitreal injection. The aqueous pharmaceutical compositions are useful for delivery of a high concentration of the antibody active ingredient to a patient without high levels of antibody aggregation and without a high level of sub-visible particulate matter. An aqueous composition of the invention comprises an antibody having a concentration of at least 50 mg/ml. An aqueous pharmaceutical composition of the invention includes a sugar, a buffering agent, and a surfactant.

Claims (10)

1. An aqueous pharmaceutical composition comprising about 120 mg/ml of an anti-VEGF antibody comprising the sequences of SEQ ID NO: 1 and SEQ ID NO: 2, about 5.8% (w/v) sucrose, 10 mM sodium citrate, and 0.02% (w/v) polysorbate 80, wherein the pH of the composition is 7.2, and wherein the composition does not have an increase in particulate matter counts greater than 10 microns after three days of shaking stress.

2. The aqueous pharmaceutical composition according to claim 1 , wherein the anti-VEGF antibody comprises the sequence of SEQ ID NO: 3 or 4.

3. The aqueous pharmaceutical composition according to claim 1 , wherein the anti-VEGF antibody comprises the sequence of SEQ ID NO: 3 and 4.

4. The aqueous pharmaceutical composition of claim 1 , comprising 120 mg/ml of the anti-VEGF antibody.

5. The aqueous pharmaceutical composition of claim 1 , comprising 5.8% (w/v) sucrose.

6. The aqueous pharmaceutical composition of claim 1 , comprising 3 mg of the anti-VEGF antibody.

7. The aqueous pharmaceutical composition of claim 1 , comprising 6 mg of the anti-VEGF antibody.

8. The aqueous pharmaceutical composition of claim 1 , wherein said composition is liquid.

9. A delivery device comprising the aqueous pharmaceutical composition of claim 1 .

10. The delivery device of claim 9 , which is a pre-filled syringe.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 20, 2019
From: SIGG, JUERGEN; DE MOOR, PAMELA
To: NOVARTIS PHARMA AG
Reel/Frame 051346/0435 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 20, 2019
From: NOVARTIS PHARMA AG
To: NOVARTIS AG
Reel/Frame 051346/0515 →
Continuity (2)
Provisional Application 62781003 · Dec 18, 2018
Related Publication 20200190179A1 · Jun 18, 2020